BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • ESG
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

July 14, 2020

11.09.2019

Society for Immunotherapy of Cancer (SITC) Annual Meeting (2019)

Validation of a Single-Blinded (Patients Only) Study Design for the Prevention of Premature Patient Consent Withdrawal in the Immuno-Oncology Trial DUBLIN-3

RECENT NEWS ARTICLES

  • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
  • BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
  • BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
  • SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
  • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
  • BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
  • BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
  • BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
  • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
  • BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

RECENT MEDIA COVERAGE

  • TD Ameritrade Watch List
  • Managing Chemotherapy Toxicities for Improved Patient Outcomes
  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
  • Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
  • Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
  • Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
Investor Contact
IR@beyondspringpharma.com
Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy